Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ridgeback Biotherapeutics

- PMLiVE

Merck to acquire Acceleron in a deal worth around $11.5bn

The acquisition of the biopharmaceutical company will complement and strengthen Merck’s cardiovascular pipeline

- PMLiVE

Mitigating misinformation: the importance of effective communication during a public health crisis

By Julie Beeso

- PMLiVE

Sanofi refocuses COVID-19 efforts away from mRNA

Trial data validates Sanofi’s mRNA and lipid nanoparticle platform but the company will not pursue its own mRNA COVID-19 vaccine

- PMLiVE

Mysterious big pharma company eyes US biotech Acceleron

Speculation is running high that a major pharma company will make a move on Massachusetts-based pulmonary and haematology biotech Acceleron this week

- PMLiVE

COVID-19 changed change and communications will never be the same

By Chris Bath

- PMLiVE

Lynparza significantly delays disease progression as first-line treatment in prostate cancer

New data show AstraZeneca and Merck‘s PARP inhibitor, Lynparza, delayed disease progression as a first-line treatment in advanced prostate cancer

- PMLiVE

COVID-19 Pfizer/BioNTech booster approved by FDA and CDC

The plan to offer Americans a third, booster shot of the Pfizer/BioNTech COVID-19 vaccine has finally been waved through by the FDA and CDC

- PMLiVE

Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%

New data showing Gilead’s Veklury cuts the risk of hospitalisation for COVID-19 contradicts results of the World Health Organization’s Solidarity study

- PMLiVE

FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer

The drug has been granted accelerated approval, and the companies have also released positive data on first-line treatment

- PMLiVE

New data from Moderna supports COVID boosters

Waning immunity from its mRNA jab “support benefit” of a booster shot, says Moderna, while international scientists publish plea for evidence over politics

EU flag

EU “still interested” in Valneva COVID vaccine despite UK snub

Negotiations between Valneva and the EU are “ongoing and advanced”, with its vaccine candidate VLA2001 touted as a potential booster shot in France

regeneron headquarters

US orders 1.4 million more doses of Regeneron antibody cocktail

The new $2.9bn order increases the amount of Regeneron’s anti-COVID REGEN-COV purchased by the US government to nearly 3 million doses

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links